# Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Brain Tumors

> **NCT04738162** · PHASE2 · COMPLETED · sponsor: **Universität Münster** · enrollment: 78 (actual)

## Conditions studied

- Brain Tumor, Pediatric

## Interventions

- **DRUG:** 5-Aminolevulinic Acid Hydrochloride, Oral

## Key facts

- **NCT ID:** NCT04738162
- **Lead sponsor:** Universität Münster
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-25
- **Primary completion:** 2025-11-24
- **Final completion:** 2025-11-24
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2025-12-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04738162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04738162, "Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Brain Tumors". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT04738162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*